Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
| Status: | Terminated |
|---|---|
| Conditions: | Blood Cancer, Blood Cancer, Lymphoma, Lymphoma, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/16/2018 |
| Start Date: | February 19, 2018 |
| End Date: | July 20, 2018 |
Long-Term Follow-up Protocol for Subjects Treated With a CAR T-Cell Product on a Juno-Sponsored Clinical Trial
This study will provide long-term follow-up for patients who have received treatment with a
Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be
followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of
delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of
replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.
Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be
followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of
delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of
replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.
Inclusion Criteria:
- Patients who have received at least one dose of a Juno CAR T-cell product (listed
above) in a Juno-sponsored clinical trial
- Patients who have provided informed consent for the long-term follow-up study
Exclusion Criteria:
- None. All patients who have previously received treatment with a Juno CAR T-cell
product are eligible for this long-term follow-up study.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials